Investment Analysts’ Recent Ratings Updates for Connect Biopharma (CNTB)

Connect Biopharma (NASDAQ: CNTB) has recently received a number of price target changes and ratings updates:

• 6/28/2026 – Connect Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 6/25/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 6/20/2026 – Connect Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/18/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
• 5/16/2026 – Connect Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/4/2026 – Connect Biopharma had its “sell (d)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In related news, Director James Huang purchased 150,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was acquired at an average price of $2.48 per share, for a total transaction of $372,000.00. Following the completion of the purchase, the director owned 13,310,000 shares in the company, valued at approximately $33,008,800. This represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.60% of the stock is currently owned by insiders.

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.